Vomiting blood, confusion, or a rapidly swelling abdomen needs emergency care immediately. These suggest advanced liver disease. Also seek urgent care for deepening jaundice.
Fat accumulates within liver cells. In most people it causes no harm, but in a minority it drives inflammation and scarring that can progress to cirrhosis and liver cancer.
The important distinction is between simple fat and fibrosis. Being told you have a fatty liver is common and usually not alarming; having significant fibrosis is a different matter, and it can be assessed without a biopsy.
Fat accumulating within liver cells, in the absence of significant alcohol intake, is now termed metabolic dysfunction-associated steatotic liver disease. It is closely linked to insulin resistance, type 2 diabetes and central obesity, and it is now among the commonest liver conditions worldwide.
It exists on a spectrum. Simple fat accumulation is common and in most people does not progress. In a minority, inflammation develops — steatohepatitis — and that inflammation drives fibrosis, which over years can progress to cirrhosis and carries a risk of liver cancer.
The critical point is that the amount of fat matters far less than the amount of scarring. Fibrosis stage is the strongest predictor of liver-related outcomes and of overall mortality, and someone with a very fatty liver and no fibrosis has a considerably better outlook than someone with less fat but advanced scarring.
It is also worth knowing that most people with fatty liver disease are more likely to be harmed by cardiovascular disease than by their liver. Treating blood pressure, cholesterol and diabetes is therefore part of treating the liver rather than a separate concern.
Being told you have a fatty liver is extremely common and by itself tells you very little about your risk. What matters is whether scarring has developed, and that can be estimated without a biopsy. The FIB-4 score is calculated from your age, platelet count and two routine liver enzymes — it costs nothing and can be worked out from blood tests you have probably already had. Transient elastography, a painless scan measuring liver stiffness, refines it further. A low FIB-4 makes advanced fibrosis unlikely and is genuinely reassuring; a raised one warrants proper assessment. Ask for this rather than accepting fatty liver as a diagnosis in itself.
Non-invasive scoring has largely replaced biopsy for assessing risk.
It needs only your age, platelet count, AST and ALT — all of which appear on routine blood tests. Send those, together with your liver ultrasound report, HbA1c, and hepatitis B and C status. Also mention your alcohol intake honestly, because the assessment and the treatment differ, and tell us about any other liver condition in the family. Those few items let us tell you whether your fatty liver is likely to be harmless or whether it needs proper attention.
Weight reduction is the most effective treatment, and the metabolic drivers must be treated alongside.
Sustained weight reduction improves liver fat, inflammation and, with greater reduction, fibrosis itself. Alongside it, tight control of diabetes, blood pressure and cholesterol, avoiding alcohol, and treating any coexisting hepatitis. This combination is the foundation of treatment and it works.
Certain diabetes medications improve liver histology as well as blood sugar, and newer agents specifically for steatohepatitis have emerged. Vitamin E has a role in selected non-diabetic patients. Treatment should be directed by someone who follows this rapidly changing field rather than chosen from an internet list.
Among the most effective interventions for fatty liver disease in patients with severe obesity, producing substantial improvement in inflammation and, in a meaningful proportion, in fibrosis. Where obesity, diabetes and fatty liver coexist, surgery addresses all three simultaneously.
Where cirrhosis has developed, six-monthly ultrasound surveillance for liver cancer becomes essential, along with endoscopy to screen for varices. These are the same measures used in cirrhosis of any cause, and they are frequently not arranged for patients whose cirrhosis arose from fatty liver.
This determines everything. Simple fat needs metabolic management; advanced fibrosis needs specialist follow-up and cancer surveillance.
Diabetes, alcohol, coexisting hepatitis B or C. Each needs its own treatment and each accelerates the liver disease.
Where severe obesity and diabetes coexist with fatty liver, one operation addresses all three.
If your FIB-4 is low and you have no other liver risk, we will tell you that this needs metabolic management rather than a liver specialist. That reassurance is worth having.
Signs of decompensated liver disease need local treatment and are not safe to travel with. Assessment for surgery follows stabilisation.
Photographs taken on your phone are fine. Reports in Arabic, Russian or Bengali are fine — we translate them ourselves.
For most people, not very. Simple fat accumulation is common and usually does not progress. What matters is whether inflammation and scarring have developed, and that can be estimated without a biopsy using the FIB-4 score and a liver stiffness scan. A low score is genuinely reassuring.
A score calculated from your age, platelet count, AST and ALT — all of which appear on routine blood tests you may already have had. It estimates the likelihood of advanced fibrosis, costs nothing extra, and is the recommended first step in assessing anyone with fatty liver. Ask your doctor to calculate it.
Substantially, yes. Sustained weight reduction improves liver fat and inflammation, and greater reduction can improve fibrosis itself. This is the most effective treatment available, and it is why bariatric surgery is among the most effective interventions in patients with severe obesity and fatty liver.
It is best avoided. Alcohol and metabolic fatty liver disease compound each other, and the combination accelerates progression to fibrosis and cirrhosis considerably. If fibrosis has already developed, complete abstinence is the right advice rather than moderation.
Usually not any more. Non-invasive scoring with FIB-4 and elastography has largely replaced biopsy for assessing risk, and biopsy is now reserved for cases where the diagnosis remains genuinely uncertain or where another liver condition is suspected alongside.
It is essential to check, particularly for patients from regions where hepatitis B and C are common — which includes most of the countries we work with. Both cause liver damage that looks similar on imaging and both are treated quite differently. Testing should be part of any fatty liver assessment.
Send your liver tests with the platelet count, your ultrasound report and hepatitis status. Your FIB-4 score can be calculated from tests you probably already have.
Your reports go directly to our medical team. We do not share your records with hospitals until you tell us to.
WhatsApp +91 83035 86344 · Phone +91 83035 86344 · Email tibhind@gmail.com
Coordinators available 9:00–20:00 IST. We speak Arabic, English, Russian and Bengali.